RS 22:1028.1
275 words·~1 min read·
/la/title-22/22-2453A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
RS 22:1028.1
§1028.1. Required coverage for breast and ovarian cancer susceptibility screening
A. The legislature hereby finds that a woman's lifetime risk of developing breast or ovarian cancer is greatly increased if she inherits a harmful mutation in the BRCA1 or BRCA2 genes. Testing for the presence of BRCA1 or BRCA2 gene mutations may allow for interventions to reduce the risk for cancer or cancer-related death in women who are BRCA mutation carriers.
B.(1) Any health coverage plan delivered or issued for delivery in this state shall include coverage for the cost of the genetic testing of the BRCA1 and BRCA2 genes to detect an increased risk for breast and ovarian cancer when recommended by a healthcare provider in accordance with the United States Preventive Services Task Force recommendations for testing.
(2)The coverage provided in this Section may be subject to annual deductibles, coinsurance, and copayment provisions as are consistent with those established under the health coverage plan.
C. For purposes of this Section, "health coverage plan" means any hospital, health, or medical expense insurance policy, hospital or medical service contract, employee welfare benefit plan, contract, or other agreement with a health maintenance organization or a preferred provider organization, health and accident insurance policy, or any other insurance contract of this type in this state, including a group insurance plan, a self-insurance plan, and the Office of Group Benefits programs.
"Health coverage plan" shall not include a plan providing coverage for excepted benefits as defined in R.S. 22:1061, limited benefit health insurance plans, and short-term policies that have a term of less than twelve months.
Acts 2019, No. 118, §1, eff. Jan. 1, 2020.